NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Cavalry Biosciences

Cavalry Biosciences

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://cavalry.bio/

Last Round

Series B

Jun 8, 2026

Total Funding Raised

$40.27M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Cavalry Biosciences is a biotechnology company developing therapeutic drugs to treat rare and chronic diseases by engineering tissue-selective growth factors and cytokines.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

antibody-biologic conjugatestissue-selective growth factorsprotein engineeringtargeted drug deliveryABCsgrowth factor engineeringbiologic therapeuticsbiologicsregenerative medicinerare disease therapeuticsdrug discovery platformpreclinical biotechophthalmology therapeuticsmusculoskeletal therapeuticsneurotrophic keratitis

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cavalry Biosciences Comparables

Compare Cavalry Biosciences with similar companies based on industry and business-model similarity.

Cavalry Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Silver Creek Pharmaceuticals
76%
miRecule, Inc.
76%
Dyne Therapeutics
67%

Cavalry Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 8, 2026
GrantSep 22, 2023
Series ANov 1, 2021

Cavalry Biosciences Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 8, 2026

    Raised $75M in Series B funding.

  • Apr 4, 2026

    Monthly visitors increased 70% MoM.

Cavalry Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cavalry Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cavalry Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range17
Year Founded2021
Last FundingJun 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.